08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

Aerosurf lucinactant: Phase IIb started

Discovery Labs began a double-blind, international Phase IIb trial to compare up to 2 repeat doses of 25 or 50 minutes of aerosolized Aerosurf plus nasal continuous positive airway pressure (nCPAP) vs. nCPAP alone in...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Aerosurf: Completed Phase IIa enrollment

Discovery Labs completed enrollment of 32 premature infants of 29-34 weeks gestational age in an open-label Phase IIa trial comparing 60 and 90 minutes of aerosolized Aerosurf plus nasal continuous positive airway pressure (nCPAP) vs....
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Aerosurf: Phase IIa data

Top-line data from an open-label, dose-escalation, U.S. Phase IIa trial in 48 premature infants receiving nasal continuous positive airway pressure (nCPAP) for RDS showed that single doses of 25, 50 and 75 mg/kg inhaled Aerosurf...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Financial News

Discovery Laboratories financial update

Discovery Laboratories Inc. (NASDAQ:DSCO), Warrington, Pa.   Business: Pulmonary   Date announced: 2015-07-22   Note: Discovery Labs raised $5.2 million through the sale of 8.7 million series A units at $0.60 to cover the overallotment...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Financial News

Discovery Laboratories completes follow-on

Discovery Laboratories Inc. (NASDAQ:DSCO), Warrington, Pa.   Business: Pulmonary   Date completed: 2015-07-17   Type: Follow-on   Raised: $35 million   Units: 58.3 million   Price: $0.60 (unit)   Shares after offering: 104.2 million  ...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

Aerosurf: Phase IIa started

Discovery Labs began an open-label Phase IIa trial to compare repeat doses of aerosolized Aerosurf plus nasal continuous positive airway pressure vs. nasal continuous positive airway pressure alone in premature infants 29-34 weeks gestational age....
07:00 , Apr 6, 2015 |  BioCentury  |  Finance

Up, up and acquired

For the first time since 1Q14, none of the biotech market cap segments fell. While the $200-$499 million tier treaded water, all other segments finished in the black, led by the $1-$4.9 billion segment. Large...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Discovery Laboratories pulmonary news

Discovery Laboratories disclosed in its 2014 financial results that it will restructure to focus on development of Aerosurf aerosolized KL4 surfactant for respiratory diseases, beginning with respiratory distress syndrome (RDS) in premature infants. Discovery Labs...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Company News

Discovery Laboratories management update

Discovery Laboratories Inc. (NASDAQ:DSCO), Warrington, Pa.   Business: Pulmonary   Departed: Russell Clayton as SVP of R&D, effective December   Transitioned: Steven Simonson to SVP and chief development officer from VP of clinical development  ...